AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca has booked its first profit from sales of its Covid-19 vaccine.

AstraZeneca is starting to profit from sales of its Covid-19 vaccine

The company said it will still sell the jab on a not-for-profit basis to poorer countries.

AstraZeneca Will Now Profit From Covid Vaccine After Pledge To Sell At Cost During Pandemic

AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine made a small contribution to earnings in Q3. It expects the shot to move to "modest profitability" on new orders.

AstraZeneca's COVID-19 Vaccine Turns Profitable In Q3; Reaffirms FY21 Guidance

The British drugmaker will house its pandemic-related assets in a separate unit.

AstraZeneca Says Covid-19 Vaccine Now Profitable. Why the Stock Is Falling.

AstraZeneca PLC (LSE:AZN) has unveiled a change of strategy with its Covid vaccine, announcing it intends to make a modest profit from sales of the jab as new orders are received. It represents a movement from the drug giant's previously stated stance as it aimed to roll out initial batches of the life-saving injections, co-developed by the University of Oxford, on a not-for-profit basis.

AstraZeneca targeting a 'modest' profit from Covid vaccine

AstraZeneca's COVID-19 vaccine contributed one cent to earnings per share in the third quarter and it expects the shot to move to "modest profitability" on new orders after the drugmaker on Friday posted $1.05 billion sales for the period.

AstraZeneca vaccine turns profitable in Q3, drugmaker banking on new orders

AstraZeneca PLC (LSE:AZN) releases third quarter results on Friday with shareholders feeling good despite the company perhaps not getting the kudos it deserved for its COVID-19 vaccine efforts. Stockbroker AJ Bell noted a positive outlook for the FTSE 100 stalwart, given the recent performance of the shares despite the weight of the COVID-19 vaccine (which is sold at cost and is overall loss making).

AstraZeneca facing raised expectations

Bakkt Holdings

The number of companies reporting quarterly earnings this week has swelled to more than 1,000 as more companies confirm their plans.

Earnings Previews: AstraZeneca, Bakkt, Hyzon

AstraZeneca PLC (LSE:AZN) was well bid during the afternoon session with analysts revisiting their spreadsheets after a flurry of news. Barclays Capital has moved its price target to £110 from £100 for shares in the Anglo-Swedish drugs giant.

AstraZeneca in demand as analysts see further upside

AstraZeneca plc (NASDAQ: AZN) is reportedly creating a separate division for vaccines and antibody therapies, primarily to focus on its COVID-19 shot and coronavirus treatments after a shaky start during the pandemic. Related Link:  AstraZeneca Looking At Potential Options for COVID-19 Vaccine Business: Reuters.

AstraZeneca Plans To Set Up Separate Division For Vaccines & Antibody Therapies - Report

AstraZeneca's(AZN) third-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on sales numbers of AstraZeneca's COVID-19 vaccine.

AstraZeneca (AZN) to Report Q3 Earnings: What's in the Cards?

(Reuters) -AstraZeneca is creating a separate division for vaccines and antibody therapies to be led by senior executive Iskra Reić, the drugmaker said on Tuesday, as it builds focus on its COVID-19 shot and development of coronavirus treatments.

AstraZeneca to create separate division for vaccines, antibody therapies

AstraZeneca has underperformed most of its US-based peers over the past year. This is due to a fairly richly valuation, both fundamental and relative.

AstraZeneca: Lagging For A Reason

AstraZeneca shared positive interim results for Imfinzi plus chemotherapy in treating patients with advanced biliary tract cancer.

These Clinical Results Are Good News for AstraZeneca

AstraZeneca has run up steeply in recent months. I like the company fine but not the valuation.

AstraZeneca: Looking Overvalued

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will present new data underscoring its commitment to transforming hematologic cancer care at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, December 11 to 14, 2021. More than 25 abstracts will feature data across the Company's hematology portfolio and pipeline, including new analyses from the CALQUENCE® (acalabrutinib) Phase III program such as an oral presentation of three-year follow-up data from the ASCEND Phase III

AstraZeneca Advances Ambition to Redefine Care for Blood Cancer at ASH 2021

In the latest trading session, Astrazeneca (AZN) closed at $63.83, marking a +0.42% move from the previous day.

Astrazeneca (AZN) Gains But Lags Market: What You Should Know

PHILADELPHIA, Nov. 3, 2021 /PRNewswire/ -- Integral Molecular, an industry leader in developing antibodies against membrane proteins, announced today that it entered into an exclusive worldwide antibody license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop therapeutics for multiple cancers. Under the terms of the agreement, Integral Molecular will provide an exclusive license to AstraZeneca for a collection of highly specific monoclonal antibodies for use in oncology.

Integral Molecular Enters into Antibody License Agreement with AstraZeneca for Oncology Therapeutics

TOKYO & MUNICH--(BUSINESS WIRE)--Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for the Treatment of HER2 Positive Advanced Gastric Cancer

Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for the Treatment of HER2 Positive Advanced Gastric Cancer

AstraZeneca PLC (LSE:AZN)'s premium growth rate and R&D story are still not fully appreciated by the market. This, at least, is the conclusion of the life sciences team at the UBS, which also believes competition fears around AZ's blockbuster cancer drug Tagrisso have been overdone.

AstraZeneca's premium growth story still not appreciated by the market, leading investment bank says

Inovio Pharmaceuticals

MedImmune Limited, a unit of AstraZeneca Plc (NASDAQ: AZN), has notified Inovio Pharmaceuticals Inc (NASDAQ: INO) to terminate the DNA cancer vaccine development program agreement. Under the agreement, MedImmune acquired exclusive rights to INO-3112 immunotherapy, renamed MEDI0457, targeting cancers caused by human papillomavirus types 16 and 18.

AstraZeneca's Medimmune Terminates DNA Cancer Vaccine Program With Inovio

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca is proud to announce contributions to 30 nonprofit, community-based organizations nationwide through the ACT on Health Equity: Community Solutions Challenge. Recipients will use the funds to accelerate positive change for underserved populations at the local level. “AstraZeneca is committed to advancing health equity in the US and we realize that this can only be done in partnership with local community leaders. The Community Solutions Challenge is

AstraZeneca Awards 30 Nonprofit Organizations through the ACT on Health Equity Community Solutions Challenge to Actively Address Health Disparities

AstraZeneca Plc (NASDAQ: AZN) will transfer global rights for respiratory medicines Eklira and Duaklir to Covis Pharma Group for $270 million. Covis will also cover certain ongoing development costs related to the medicines.

AstraZeneca To Offload Some Drug Rights To Covis Pharma For $270M

argenx

Ocugen, Inc.

Could these biotech stocks be top buys as investors digest the latest earnings figures?

Best Stocks To Buy This Week? 3 Biotech Names To Know

AstraZeneca Plc (NASDAQ: AZN) revealed topline results from the Phase 3 TOPAZ-1 study. Related:   AstraZeneca Touts Longest Survival Update In Lung Cancer Setting With Imfinzi/Chemo Data.

News for AstraZeneca Stock (AZN)